Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Cardiovascular·MeSH: Cardiovascular Diseases
Prevalence
6000.0 / 100K
Incidence
500.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| tqj230 | Novartis AG (NVS) |
Frequently asked questions
How many drugs are in development for Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease?
BioSniper tracks 1 drug in development for Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease across 1 company.
How many clinical trials target Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease?
There are 1 clinical trial targeting Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease tracked by BioSniper.
What is the prevalence of Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease?
The estimated prevalence of Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease is approximately 6000.0 per 100,000 population.
Deep-dive into Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis